Derivative

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Tuesday, June 22, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

LYDALL ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of LDL and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 21, 2021
Corporate finance, Stock market, Finance, Money, Corporations, Security, Derivative, Mergers and acquisitions, Stock

On June 21, 2021, Lydall announced that it had signed an agreement to merge with Unifrax for approximately $1.3 billion.

Key Points: 
  • On June 21, 2021, Lydall announced that it had signed an agreement to merge with Unifrax for approximately $1.3 billion.
  • Pursuant to the merger agreement, Lydall stockholders will receive $62.10 in cash for each share of Lydall common stock owned.
  • Bragar Eagel & Squire is concerned that Lydalls board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

RAVEN INDUSTRIES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of RAVN and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, June 21, 2021
Economy, CNH Industrial, Fiat, Companies, Security, Derivative, Mergers and acquisitions, Business

On June 21, 2021, Raven announced that it had signed an agreement to merge with CNH Industrial for approximately $2.1 billion.

Key Points: 
  • On June 21, 2021, Raven announced that it had signed an agreement to merge with CNH Industrial for approximately $2.1 billion.
  • Pursuant to the merger agreement, Raven stockholders will receive $58 in cash for each share of Raven common stock owned.
  • Bragar Eagel & Squire is concerned that Ravens board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Schulte Roth & Zabel Announces Addition of Leading Finance Lawyer Gregory Ruback

Retrieved on: 
Monday, June 21, 2021
Legal, Professional services, Schulte Roth & Zabel, Zabel, Schulte, Derivative

Schulte Roth & Zabel (SRZ) announces the addition of Gregory Ruback as a partner in the Finance & Derivatives Group, resident in the firms New York office.

Key Points: 
  • Schulte Roth & Zabel (SRZ) announces the addition of Gregory Ruback as a partner in the Finance & Derivatives Group, resident in the firms New York office.
  • Greg is a market-leading lawyer with specialist expertise, and we are thrilled to welcome him to SRZ, said Craig Stein, co-head of the Finance & Derivatives Group.
  • Greg is an excellent addition to our leading finance and derivatives group, which represents some of the prominent players in the market.
  • Schulte Roth & Zabel LLP ( www.srz.com ) is a full-service law firm with offices in New York, Washington, DC and London.